Ipamorelin at a Glance

• Ipamorelin is a synthetic pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH₂, developed at Novo Nordisk under the code NNC 26-0161 and described in the literature as the first selective growth hormone secretagogue.
• It is an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a) the receptor through which endogenous ghrelin acts, making it a ghrelin-receptor mimetic, not a growth hormone analogue and not a GHRH analogue.
• Selectivity was the explicit design goal. GHRP-6, GHRP-2 and hexarelin release growth hormone but also raise ACTH, cortisol and prolactin. Ipamorelin was reported to release growth hormone without raising ACTH or cortisol above the levels seen after GHRH stimulation.
• For a musculoskeletal readership the relevant preclinical endpoints are bone and body composition: ipamorelin increased longitudinal bone growth and bone mineral content in rat models, through the GH/IGF-1 axis rather than any direct action on bone or muscle.
• It is frequently discussed alongside a GHRH analogue such as CJC-1295 on a pulsatile-release rationale that is mechanistically coherent but far less well evidenced than its popularity suggests.
• Human data are thin. The only substantial clinical programme was in postoperative ileus not in musculoskeletal indications, and it did not reach approval. Ipamorelin is not an approved drug anywhere; laboratory material is research-use-only.

What Is Ipamorelin?

Ipamorelin is a five-residue synthetic peptide, Aib-His-D-2-Nal-D-Phe-Lys-NH₂ catalogued in PubChem as CID 9831659 with molecular formula C₃₈H₄₉N₉O₅ and a molecular weight of roughly 712 Da. Three of its five residues are non-standard, and that is the whole point of the molecule.

Aib is α-aminoisobutyric acid, a quaternary, achiral residue with two methyl groups on the α-carbon; it is not a substrate for mammalian aminopeptidases, so placing it at position one both constrains the backbone and protects the N-terminus. D-2-Nal is D-2-naphthylalanine, an unnatural aromatic residue with a bulky bicyclic side chain; D-Phe at position four inverts the stereochemistry of an ordinary aromatic residue; and the C-terminus is amidated. The result is a short peptide that survives in plasma long enough to be pharmacologically useful and presents a specific arrangement of aromatic bulk to its receptor. That aromatic pair is the recognition element shared across the peptidyl secretagogues, and the differences between them lie in what surrounds it.

Ipamorelin emerged from a Novo Nordisk programme whose objective was not potency; potent secretagogues already existed. The objective was a compound that would release growth hormone without the corticotroph and lactotroph activity that had accumulated around the earlier hexapeptides, because that off-axis activity was the principal obstacle to developing any of them as a medicine. The defining paper, Raun and colleagues (1998, PMID 9849822), is titled for exactly that claim: Ipamorelin, the first selective growth hormone secretagogue.

How Does Ipamorelin Work?

GHS-R1a: The Receptor and Its Endogenous Ligand

The growth hormone secretagogue receptor was cloned before its natural ligand was known. Howard and colleagues (1996, PMID 8688086) identified a G-protein-coupled receptor in pituitary and hypothalamus mediating the growth-hormone-releasing action of the synthetic secretagogues, an orphan receptor defined by the drugs that hit it. Three years later Kojima and colleagues (1999, PMID 10604470) identified ghrelin an acylated 28-residue peptide from stomach, as the endogenous ligand. The synthetic compounds came first; the physiology was reconstructed afterwards.

GHS-R1a signals principally through Gq/11 and phospholipase C raising inositol trisphosphate and intracellular calcium in pituitary somatotrophs and triggering exocytosis of stored growth hormone. It is expressed in the anterior pituitary and in the hypothalamic arcuate nucleus, on neurons that also modulate somatostatin tone. That dual localisation matters: an agonist acts directly on the somatotroph and indirectly by reducing the somatostatin brake, which is why secretagogue-evoked release is larger than either mechanism alone would predict.

Ipamorelin is a full agonist with no established activity at any other named target. Raun and colleagues reported an ED₅₀ for growth hormone release of roughly 80 nmol/kg in anaesthetised rats and 2.3 nmol/kg in conscious swine reported here as the original investigators reported them, in the named animal models.

Why Selectivity Was the Design Goal

This is the most-cited property of ipamorelin and it deserves a precise statement. In the same 1998 comparison, GHRP-6 and GHRP-2 produced measurable increases in plasma ACTH and cortisol. Ipamorelin did not: its ACTH and cortisol responses were not significantly different from those seen after GHRH stimulation, and that separation held at doses more than 200-fold above the ED₅₀ for growth hormone release. In swine, none of the secretagogues tested altered FSH, LH, prolactin or TSH.

The human comparator data run the same way. Arvat and colleagues (1997, PMID 9285939) examined GHRP-2 and hexarelin in man against GHRH, TRH and human CRH, and reported that both hexapeptides raised prolactin, ACTH and cortisol alongside growth hormone. The corticotroph effect is not an artefact of one laboratory or one species.

Why this happens is not fully resolved; the conventional explanation is that the hexapeptides recruit hypothalamic CRH- and vasopressin-containing pathways in addition to acting on the somatotroph. What matters for research design is the consequence: a study using ipamorelin can attribute an observed effect to the GH/IGF-1 axis with far more confidence than the same study using GHRP-6 because the confounding rise in glucocorticoid is largely absent. Cortisol is itself catabolic for bone and muscle.

The GH/IGF-1 Axis Downstream of a Pulse

Ipamorelin does not act on muscle or bone. It acts on the pituitary, and everything downstream follows from growth hormone, which binds a class I cytokine receptor signalling through JAK2/STAT5. The dominant systemic consequence is hepatic transcription of IGF-1 which circulates bound to IGFBP-3 and the acid-labile subunit and acts on the type 1 IGF receptor in peripheral tissues. In skeletal muscle, that engagement activates PI3K/Akt/mTOR increasing protein synthesis and suppressing the FoxO-dependent atrophy programme; in bone, the axis acts on the growth plate in growing animals and on remodelling in adults.

The practical implication is that IGF-1 is the more stable readout. A single ipamorelin pulse produces a growth hormone spike measurable in minutes and gone within an hour or two; circulating IGF-1 integrates exposure over days, so a study sampling growth hormone at one timepoint and finding nothing may simply have missed the pulse.

Pulsatility and the GHRH Co-Stimulation Rationale

Growth hormone is secreted in discrete pulses several per day, with the largest in early slow-wave sleep and near-undetectable troughs between them. That pattern is generated by the reciprocal oscillation of hypothalamic GHRH and somatostatin, and it is not decorative: continuous and pulsatile exposure delivering the same total produce different hepatic gene-expression outcomes in animal models.

The rationale for combining a ghrelin-receptor agonist with a GHRH analogue rests on this. The two act on different receptors with different signalling GHS-R1a through Gq/PLC, the GHRH receptor through Gs/cAMP/PKA, on the same somatotroph, and the combination is reported to produce a response larger than the sum of the two given separately. Because release still comes from the pituitary’s own pool and remains subject to IGF-1 feedback and somatostatin tone, the claim is that the pattern stays pulsatile unlike the sustained elevation produced by recombinant growth hormone.

Two qualifications belong alongside that claim. First, the synergy is documented as an acute pituitary phenomenon; what is not documented is that any co-administration schedule produces a superior bone or body-composition outcome in any species. Second, a long-acting GHRH analogue, one carrying a drug affinity complex extending its half-life to days, argues against the pulsatility rationale rather than for it, since sustained receptor occupancy is by definition not pulsatile. The mechanistic story and the popular framing have drifted apart, and a research programme should be clear which of the two it is testing.

Research Evidence

Pituitary Cell and Isolated-Tissue Work

The foundational characterisation used rat pituitary cell cultures alongside anaesthetised rats and conscious swine. In primary somatotroph culture, ipamorelin produces concentration-dependent growth hormone release with an EC₅₀ in the low nanomolar range, blocked by GHS-R1a antagonism, the assay that establishes receptor-mediated action rather than a non-specific secretagogue effect. Concentrations here are reported in nanomolar terms in the named cell system and are not convertible to any in vivo exposure.

Somatotroph responsiveness also declines with repeated or continuous exposure, consistent with receptor desensitisation and depletion of the readily releasable pool, so any experiment using repeated administration needs a schedule-controlled design.

Bone: Longitudinal Growth and Mineral Content

This is the preclinical literature most relevant to a musculoskeletal readership, and it is genuinely positive. Johansen and colleagues (1999, PMID 10373343) reported that ipamorelin induces longitudinal bone growth in rats measured as increased tibial epiphyseal growth-plate width and increased longitudinal growth rate, the classic GH-axis readout in a growing animal.

Svensson and colleagues (2000, PMID 10828840) extended this to the adult skeleton, reporting that ipamorelin and GHRP-6 increase bone mineral content in adult female rats. That is the more interesting of the two studies for anyone thinking about musculoskeletal endpoints, because an effect on mineral content in a skeletally mature animal cannot be explained by growth-plate activity and implies a shift in remodelling balance. A separate line of rat work reported that ipamorelin counteracted glucocorticoid-induced suppression of bone formation a finding consistent with the cortisol-sparing argument, since a secretagogue that raised cortisol itself would be a poor candidate for that model.

Doses here are reported in conventional preclinical terms: subcutaneous administration in rats in the microgram-to-milligram per kilogram range typically once or twice daily over weeks. These figures appear strictly as the cited animal studies report them, and do not translate to any other species, route or context.

Lean Mass and Body Composition

The body-composition literature for ipamorelin specifically is thinner than the bone literature and thinner than its reputation implies. Chronic administration in young female rats has been reported to increase body weight gain and to alter in vitro pituitary growth hormone release, a body-mass rather than a body-composition endpoint. The broader claim, that ipamorelin increases lean mass and accelerates recovery from musculoskeletal injury, rests mostly on inference from the GH/IGF-1 axis rather than on direct measurement of ipamorelin in those models.

That inference is not unreasonable: ghrelin-receptor agonists as a class have been developed for cancer cachexia on exactly that basis, with anamorelin carrying furthest. But the class is not the compound, and anamorelin’s body-composition data do not transfer to ipamorelin.

Gastrointestinal Motility and the Postoperative Ileus Programme

The largest body of applied work on ipamorelin has nothing to do with musculoskeletal biology. Ghrelin is a prokinetic signal: GHS-R1a is expressed on enteric neurons and vagal afferents, and receptor agonism accelerates gastric emptying and small-bowel transit independently of growth hormone. That made it an attractive target for postoperative ileus. Venkova and Greenwood-Van Meerveld (2009, PMID 19289567) reported ipamorelin effective in a rodent model of that condition, accelerating recovery of gastrointestinal transit after surgical manipulation of the gut, and on that basis the compound was carried into clinical development by Helsinn Therapeutics.

Two registered trials define the programme. NCT00672074 was a phase 2 study enrolling 117 participants between 2008 and 2009, with recovery of gastrointestinal function as the primary outcome; a proof-of-concept report from that work (Beck and colleagues, International Journal of Colorectal Disease, 2014) described a prospective randomised controlled study of intravenous ipamorelin in bowel-resection patients. NCT01280344 followed, a larger study of 320 participants across three intravenous dose levels against saline placebo, running from 2011 to 2014 with the same primary endpoint. Both are recorded as completed. Neither led to approval and ipamorelin was not subsequently marketed for ileus or anything else, the quiet end of that programme is the most informative fact in the compound’s clinical record.

Human Data, How Thin It Really Is

Setting the ileus programme aside, published human pharmacology on ipamorelin amounts to very little. A pharmacokinetic-pharmacodynamic modelling study in human volunteers (Gobburu and colleagues, Pharmaceutical Research, 1999) characterised the relationship between exposure and growth hormone release in healthy subjects. Beyond that and the ileus trials there is no substantial clinical literature, no controlled study of body composition or bone density, no long-term safety dataset, and nothing at all in musculoskeletal injury or recovery. The preclinical bone data are real. The selectivity data are real and well replicated. The human musculoskeletal data do not exist.

What Remains Unknown

Whether selectivity survives chronic administration. The cortisol-sparing finding is an acute-challenge result. Whether the separation between growth hormone and corticotroph activation persists over weeks of repeated exposure has not been characterised, and receptor desensitisation could in principle affect the two responses differently. Sustained IGF-1 elevation raises the standard questions about insulin sensitivity and tissue proliferation, and those are unanswered here.

Whether the ileus programme failed on efficacy or on something else. Registry entries record completion, not conclusions. Without published results from the 320-patient study the reason it stopped is not in the public record, and readers should be sceptical of any source that asserts one.

Comparison

Ipamorelin Against the Earlier Peptidyl Secretagogues

Ipamorelin is not the most potent secretagogue in the class. It is the one whose effect can be attributed to growth hormone with the fewest competing explanations, which in a musculoskeletal experiment is worth more than potency.

Ipamorelin and CJC-1295, With and Without DAC

The cleanest published human data on the GHRH side come from Teichman and colleagues (2006, PMID 16352683), who reported prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295 in healthy adults, the study that established the drug-affinity-complex approach as pharmacologically real. It is also the source of the awkward observation noted above: the DAC version’s selling point is that it is not short-acting, which sits uneasily beside a rationale built on preserving pulsatility. Catalogues list CJC-1295 and CJC-1295 no DAC as separate research compounds precisely because the two behave differently, and a design that treats them as interchangeable has confounded its own variable.

Handling and Reconstitution of Lyophilised Ipamorelin

At five residues and roughly 712 Da, ipamorelin is a small, robust peptide by the standards of the research catalogue. It has no cysteine, no methionine and no tryptophan which removes disulphide scrambling and the two commonest oxidation routes in one go. The stability questions that remain are the C-terminal amide, which can hydrolyse in solution, and the histidine, which can undergo metal-catalysed oxidation in the presence of trace transition metals.

It is freely water-soluble the lysine gives a net positive charge at neutral pH and there is no hydrophobic core, so aqueous diluent is appropriate with no organic co-solvent. And it adsorbs to surfaces: a small cationic peptide binds readily to glass and untreated polypropylene, and at the dilute concentrations used in cell work this is a real and frequently unrecognised cause of apparent potency loss between preparation and assay. Low-binding tubes and tips matter more than most protocols acknowledge.

Reconstitution follows the standard sequence. Allow the vial to reach room temperature before opening, so condensation does not form on a cold cake. Disinfect the septum with 70% isopropyl alcohol and let it dry. Introduce the diluent slowly, down the inner wall of the vial rather than jetting it onto the cake, since a stream striking the cake generates local shear and a large air–liquid interface. Swirl or roll gently; never shake.

Where a vial is entered repeatedly, a preserved monographed diluent is the conventional choice, and bacteriostatic water listed alongside research compounds at NextGenPeps, or an equivalent Bacteriostatic Water for Injection, USP product, is what most protocols specify. Two caveats belong in the record. The benzyl alcohol preservative is not inert toward peptides, the formulation literature documents preservative-promoted unfolding and aggregation across several model peptides, so a single-entry analytical preparation is better served by unpreserved sterile water. And Bacteriostatic Water for Injection is contraindicated in neonatal use because of benzyl alcohol toxicity.

Store reconstituted solution at 2–8 °C, protected from light, and aliquot at the point of reconstitution rather than freeze-thawing one vial repeatedly. Record the concentration in mg/mL rather than the volume added, and log the diluent lot alongside the peptide lot.

Is Ipamorelin FDA Approved?

No. Ipamorelin is not approved by the FDA or by any other national medicines regulator for any indication, in any formulation.

The compound reached phase 2 clinical development for postoperative ileus under a commercial sponsor, completed the registered studies recorded on ClinicalTrials.gov, and was not carried to approval. There is no marketing authorisation, no approved labelling, no approved route of administration and no regulated manufacturing standard for ipamorelin anywhere.

Material sold to laboratories is therefore research-use-only in the full sense: unlike some compounds in the research catalogue, there is no approved product elsewhere whose existence could be misread as conferring status. Vials carry no established sterility or endotoxin specification, no pharmacopoeial identity standard and no approved indication. Growth hormone secretagogues as a class are also prohibited at all times under the World Anti-Doping Agency Prohibited List and ipamorelin is named in that category; laboratories in sport-science contexts should verify the current list directly. Separately, ipamorelin has been the subject of formal FDA consideration regarding its eligibility as a compounding ingredient, consideration, not settled acceptance.

Where to Source Research-Grade Ipamorelin

Because no regulator underwrites research material, the purchase record is the only evidence a laboratory has. A defensible one contains:

• A lot-matched certificate of analysis tied to the specific lot shipped rather than a representative batch from an earlier synthesis.
• Third-party HPLC purity data with a named laboratory and a test date. The realistic impurities here are deletion sequences from incomplete coupling at the sterically demanding D-2-Nal position, epimerisation at the D-residues, and free acid from incomplete C-terminal amidation, none of which a low-resolution chromatogram resolves.
• Mass spectrometry confirming identity with an observed mass consistent with the expected ~712 Da free base. Mass spectrometry cannot distinguish D- from L-residues, which is why synthesis documentation matters alongside the certificate.
• Declared net peptide content distinct from gross vial fill weight, since counterion and residual water account for a substantial fraction of the mass in a small peptide.
• Cold-chain shipping and light-protective packaging and explicit research-use-only labelling with no suggested protocol, dosing guidance or human-use framing anywhere in the listing.

Red flags are mostly absences and overreaches. A certificate with no laboratory name, test date or lot reference is decoration rather than evidence, and a supplier who will not produce documentation for the lot in hand has answered the question. Purity claims of “99%+” with no chromatogram, no method and no named laboratory are marketing, not data. A listing that supplies an injection schedule, a human protocol, a “cycle length” or any therapeutic claim has left the research-use-only frame entirely. A catalogue that lists Ipamorelin as a research compound can be assessed against exactly these criteria: lot-matched third-party analysis, identity confirmed by mass spectrometry, declared net peptide content, cold-chain handling, and research-use-only labelling with no protocol content attached.

Frequently Asked Questions

Is ipamorelin a growth hormone?

No. Ipamorelin is a five-residue synthetic peptide that binds GHS-R1a on pituitary somatotrophs and stimulates release of the animal’s own stored growth hormone. Recombinant growth hormone is a 191-amino-acid protein acting directly on the growth hormone receptor in peripheral tissues. The two produce different exposure patterns, an evoked pulse subject to normal feedback, against a sustained exogenous elevation, and are not substitutes in study design.

What makes ipamorelin “selective”?

Selectivity here means selectivity of the hormonal response not receptor selectivity in the usual sense; every peptidyl secretagogue in this class acts at GHS-R1a. In the 1998 characterisation, GHRP-6 and GHRP-2 raised plasma ACTH and cortisol while ipamorelin did not raise either above the level seen after GHRH stimulation, and that separation held at doses more than 200-fold above the growth-hormone ED₅₀.

Why is ipamorelin so often discussed alongside CJC-1295?

Because the two act on different receptors on the same cell: ipamorelin engages GHS-R1a through Gq and phospholipase C, a GHRH analogue engages the GHRH receptor through Gs and cAMP. Acute co-stimulation of both produces a larger growth hormone response than either alone. What has not been shown is that any particular schedule produces a better bone or body-composition outcome than either compound alone, in any species.

Did ipamorelin ever reach clinical trials?

Yes, but not for a musculoskeletal indication. Its clinical programme was in postoperative ileus, run by Helsinn Therapeutics: a phase 2 study of 117 participants (NCT00672074) and a larger 320-participant study of three intravenous dose levels against placebo (NCT01280344), both recorded as completed. Neither led to approval, and the compound was never marketed.

What doses appear in the animal literature?

Raun and colleagues reported an ED₅₀ for growth hormone release of approximately 80 nmol/kg in anaesthetised rats and 2.3 nmol/kg in conscious swine. The rat bone studies used subcutaneous administration in the microgram-to-milligram per kilogram range, typically daily over weeks. These figures are reported as the original investigators reported them, in the named animal models, and are not recommendations or equivalents for any other species, route or context.

Is ipamorelin banned in sport?

Growth hormone secretagogues are prohibited at all times under the World Anti-Doping Agency Prohibited List, in the peptide hormones, growth factors, related substances and mimetics category, and ipamorelin is named within that class. Anyone working in a tested environment should consult the current list directly; prohibited-list categories are revised annually.

The Bottom Line

Ipamorelin is the cleanest tool in the growth hormone secretagogue class, and that is a precise compliment rather than a general one. It is not the most potent compound at GHS-R1a and was never meant to be. What the Novo Nordisk programme achieved was separation: growth hormone release without the ACTH and cortisol elevation that accompanies GHRP-6, GHRP-2 and hexarelin, sustained across a 200-fold dose range. For any experiment in which cortisol is itself an active variable, and in bone and skeletal muscle, it always is, that separation is what makes the compound useful.

The preclinical musculoskeletal record supports the mechanism at the level it was tested: increased longitudinal bone growth in growing rats, increased bone mineral content in adult female rats, and counteraction of glucocorticoid-induced suppression of bone formation. Those are the strongest part of the file.

What the file does not contain is human musculoskeletal data. The only substantial clinical programme was in postoperative ileus, an indication chosen because ghrelin-receptor agonism is prokinetic, nothing to do with bone or muscle, and it completed two registered trials and stopped without approval. There is no controlled human study of ipamorelin on lean mass, bone density or recovery from injury.

The commonest error in secondary coverage is treating the ghrelin-mimetic class as interchangeable, reading anamorelin’s cachexia data onto ipamorelin; the second is presenting the GHRH co-administration rationale as an established finding when it remains an acute pituitary observation in search of an outcome study. A laboratory using ipamorelin as a selective probe of GH/IGF-1 axis biology, with IGF-1 as the integrating readout and a schedule-controlled design, is using it for what the evidence supports.

By [AUTHOR NAME PLACEHOLDER], [CREDENTIALS PLACEHOLDER]. Fact-checked by [FACT-CHECKER NAME PLACEHOLDER].

Research Use Only Disclaimer

Ipamorelin and all other compounds discussed in this article are intended for laboratory research use only. Ipamorelin is not an approved drug product in any jurisdiction: no marketing authorisation, no approved labelling, no regulated manufacturing or sterility standard, no approved route of administration and no approved indication.

Nothing here is medical, veterinary or pharmaceutical advice, and nothing constitutes a dosing recommendation, a protocol for use in humans or animals, or a therapeutic claim of any kind. Research peptides described here are not for human or veterinary use. Doses and concentrations quoted from the literature are reported in the terms the original investigators used, nanomoles or milligrams per kilogram in the named animal model, or molar concentrations in the named cell system, and are not recommendations, conversions or equivalents for any other species, route or context. Descriptions of clinical trial records summarise the published scientific and regulatory record, not what any compound does in any individual.

Growth hormone secretagogues are prohibited at all times under the World Anti-Doping Agency Prohibited List. Bacteriostatic Water for Injection, USP contains benzyl alcohol and is contraindicated in neonates. Readers with clinical questions should consult a qualified healthcare professional, and are responsible for compliance with all applicable laws, institutional review and animal ethics requirements, anti-doping regulations and biosafety rules in their jurisdiction.

Related posts:

How Advanced Nursing Roles Are Improving Patient Care Outcomes 6 Best Remineralizing Toothpaste For Enamel Repair: Picks for Sensitive Teeth, Receding Gums, and Early Erosion How Healthcare Is Evolving to Meet Modern Patient Needs How Motion-Tracking Gadgets Improve Physical Therapy Accuracy Buy BPC-157 Peptide: Dosage, Side Effects, and How To Get BPC-157 Products in 2026 Best Peptides for Muscle Growth: A Research-Based Look at the Top Options

Stay updated, free articles. Join our Telegram channel

Join